Kevin Klein

1.6k total citations
29 papers, 1.2k citations indexed

About

Kevin Klein is a scholar working on Immunology, Economics and Econometrics and Virology. According to data from OpenAlex, Kevin Klein has authored 29 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Economics and Econometrics and 7 papers in Virology. Recurrent topics in Kevin Klein's work include Biosimilars and Bioanalytical Methods (8 papers), Pharmaceutical Economics and Policy (8 papers) and HIV Research and Treatment (7 papers). Kevin Klein is often cited by papers focused on Biosimilars and Bioanalytical Methods (8 papers), Pharmaceutical Economics and Policy (8 papers) and HIV Research and Treatment (7 papers). Kevin Klein collaborates with scholars based in United States, Netherlands and Denmark. Kevin Klein's co-authors include Jaisri R. Lingappa, Michael H. Malim, Rebecca K. Holmes, Heather M. Craig, Ann M. Sheehy, Patti Kiser, Pieter Stolk, Bonnie L. Firestein, Stephen J. Polyak and M. Juliana McElrath and has published in prestigious journals such as Nature, Journal of Biological Chemistry and The Journal of Cell Biology.

In The Last Decade

Kevin Klein

29 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kevin Klein United States 17 642 466 369 347 318 29 1.2k
Yoshiyuki Yokomaku Japan 20 699 1.1× 366 0.8× 283 0.8× 654 1.9× 193 0.6× 60 1.1k
Thierry Huet France 13 713 1.1× 423 0.9× 296 0.8× 482 1.4× 203 0.6× 18 1.2k
Shibo Jiang China 19 279 0.4× 482 1.0× 296 0.8× 606 1.7× 301 0.9× 60 1.4k
Emmanuel Cormier United States 14 899 1.4× 428 0.9× 446 1.2× 499 1.4× 586 1.8× 17 1.7k
Julie Mori United Kingdom 14 948 1.5× 332 0.7× 312 0.8× 1.0k 2.9× 317 1.0× 25 1.7k
Patrick Dorr United Kingdom 10 930 1.4× 409 0.9× 198 0.5× 705 2.0× 337 1.1× 17 1.4k
M Groenink Netherlands 13 1.2k 1.9× 251 0.5× 200 0.5× 833 2.4× 466 1.5× 17 1.4k
Kazuhisa Yoshimura Japan 25 1.4k 2.2× 580 1.2× 284 0.8× 1.3k 3.7× 396 1.2× 80 2.1k
Barbara Maschera United Kingdom 15 525 0.8× 492 1.1× 205 0.6× 562 1.6× 606 1.9× 20 1.7k
Chi‐Cheng Luo United States 21 925 1.4× 517 1.1× 350 0.9× 890 2.6× 119 0.4× 26 1.7k

Countries citing papers authored by Kevin Klein

Since Specialization
Citations

This map shows the geographic impact of Kevin Klein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kevin Klein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kevin Klein more than expected).

Fields of papers citing papers by Kevin Klein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kevin Klein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kevin Klein. The network helps show where Kevin Klein may publish in the future.

Co-authorship network of co-authors of Kevin Klein

This figure shows the co-authorship network connecting the top 25 collaborators of Kevin Klein. A scholar is included among the top collaborators of Kevin Klein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kevin Klein. Kevin Klein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Klein, Kevin, et al.. (2024). Synthetic polypeptides using a biologic as a reference medicinal product – the European landscape of regulatory approvals. Frontiers in Medicine. 11. 1335928–1335928. 1 indexed citations
2.
3.
Klein, Kevin, et al.. (2022). Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?. Therapeutic Innovation & Regulatory Science. 56(2). 366–377. 9 indexed citations
4.
Leufkens, Hubert G. M., Murray Aitken, Jarno Hoekman, et al.. (2022). Four scenarios for the future of medicines and social policy in 2030. Drug Discovery Today. 27(8). 2252–2260. 6 indexed citations
5.
Klein, Kevin, Pieter Stolk, Marie L. De Bruin, & Hubert G. M. Leufkens. (2021). Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines. Drug Discovery Today. 26(10). 2221–2225. 4 indexed citations
6.
Klein, Kevin, Gerrit Borchard, Vinod P. Shah, et al.. (2021). A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways. Annals of the New York Academy of Sciences. 1502(1). 5–13. 17 indexed citations
7.
Klein, Kevin, Pieter Stolk, Marie L. De Bruin, et al.. (2019). The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations. European Journal of Pharmaceutical Sciences. 133. 228–235. 42 indexed citations
8.
Klein, Kevin, Lorna Hazell, Pieter Stolk, & Saad Shakir. (2019). The UK BIO-TRAC Study: A Cross-Sectional Study of Product and Batch Traceability for Biologics in Clinical Practice and Electronic Adverse Drug Reaction Reporting in the UK. Drug Safety. 43(3). 255–263. 5 indexed citations
9.
Klein, Kevin & Pieter Stolk. (2018). Challenges and Opportunities for the Traceability of (Biological) Medicinal Products. Drug Safety. 41(10). 911–918. 20 indexed citations
10.
Danhof, Meindert, Kevin Klein, Pieter Stolk, Murray Aitken, & Hubert G. M. Leufkens. (2018). The future of drug development: the paradigm shift towards systems therapeutics. Drug Discovery Today. 23(12). 1990–1995. 24 indexed citations
11.
12.
Klein, Kevin, Marie L. De Bruin, André W. Broekmans, & Pieter Stolk. (2015). Classification of Recombinant Biologics in the EU: Divergence Between National Pharmacovigilance Centers. BioDrugs. 29(6). 373–379. 2 indexed citations
13.
Jackson, Fleda Mask, et al.. (2014). Save 100 Babies©: Engaging Communities for Just and Equitable Birth Outcomes Through Photovoice and Appreciative Inquiry. Maternal and Child Health Journal. 18(8). 1786–1794. 8 indexed citations
14.
Thielen, Beth K, et al.. (2010). Innate Immune Signaling Induces High Levels of TC-specific Deaminase Activity in Primary Monocyte-derived Cells through Expression of APOBEC3A Isoforms. Journal of Biological Chemistry. 285(36). 27753–27766. 89 indexed citations
15.
Thielen, Beth K, et al.. (2007). T Cells Contain an RNase-Insensitive Inhibitor of APOBEC3G Deaminase Activity. PLoS Pathogens. 3(9). e135–e135. 39 indexed citations
16.
Lingappa, Jaisri R., et al.. (2005). Comparing capsid assembly of primate lentiviruses and hepatitis B virus using cell-free systems. Virology. 333(1). 114–123. 18 indexed citations
17.
Holmes, Rebecca K., Heather M. Craig, Kevin Klein, et al.. (2005). Antiviral Function of APOBEC3G Can Be Dissociated from Cytidine Deaminase Activity. Current Biology. 15(2). 166–170. 410 indexed citations
18.
Klein, Kevin, et al.. (2005). Identification of Residues in the Hepatitis C Virus Core Protein That Are Critical for Capsid Assembly in a Cell-Free System. Journal of Virology. 79(15). 10098–10098. 2 indexed citations
19.
Klein, Kevin, et al.. (2002). Identification of a host protein essential for assembly of immature HIV-1 capsids. Nature. 415(6867). 88–92. 187 indexed citations
20.
Margolis, Stephen A, et al.. (2001). Improving Performance at the Local Level. Journal of Public Health Management and Practice. 7(4). 96–104. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshiyuki Yokomaku Breakdown of academic impact, for papers by Thierry Huet Breakdown of academic impact, for papers by Shibo Jiang Breakdown of academic impact, for papers by Emmanuel Cormier Breakdown of academic impact, for papers by Julie Mori Breakdown of academic impact, for papers by Patrick Dorr Breakdown of academic impact, for papers by M Groenink Breakdown of academic impact, for papers by Kazuhisa Yoshimura Breakdown of academic impact, for papers by Barbara Maschera Breakdown of academic impact, for papers by Chi‐Cheng Luo
Rankless by CCL
2026